Stay updated on Eribulin + Pembrolizumab in Soft Tissue Sarcomas Clinical Trial

Sign up to get notified when there's something new on the Eribulin + Pembrolizumab in Soft Tissue Sarcomas Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Eribulin + Pembrolizumab in Soft Tissue Sarcomas Clinical Trial page

  1. Check
    today
    Change Detected
    Summary
    The expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.
    Difference
    0.6%
    Check dated 2025-06-20T22:07:00.000Z thumbnail image
  2. Check
    7 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.2 to version 2.16.3.
    Difference
    0.1%
    Check dated 2025-06-13T16:34:11.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.2.
    Difference
    0.1%
    Check dated 2025-06-06T10:28:34.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    The web page has announced a modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, providing API users an opportunity to give input before implementation.
    Difference
    1%
    Check dated 2025-05-30T06:09:00.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    The web page has been updated to version 2.16.0, replacing the previous version 2.15.2.
    Difference
    0.2%
    Check dated 2025-05-23T02:24:53.000Z thumbnail image
  6. Check
    51 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.1%
    Check dated 2025-05-01T06:27:02.000Z thumbnail image

Stay in the know with updates to Eribulin + Pembrolizumab in Soft Tissue Sarcomas Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Eribulin + Pembrolizumab in Soft Tissue Sarcomas Clinical Trial page.